Eastern Journal of Psychiatry

Register      Login

VOLUME 24 , ISSUE 1 ( January-June, 2024 ) > List of Articles

CASE REPORT

Risperidone-induced Priapism: A Rare Case Report

Priyajyoti Chakma, Bhubaneswar Roy, Arnab Deb

Keywords : Adverse effects, Antipsychotics, Case report, Ischemia, Penis

Citation Information : Chakma P, Roy B, Deb A. Risperidone-induced Priapism: A Rare Case Report. 2024; 24 (1):24-25.

DOI: 10.5005/jp-journals-11001-0073

License: CC BY-NC 4.0

Published Online: 08-06-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Priapism is a rare pathological condition in which a penis remains erect for an hour in the absence of stimulation or after stimulation has ended. Priapism can be of ischemic, nonischemic, and recurrent ischemic types. Ischemic type is also known as low-flow and likewise nonischemic as high-flow as well as recurrent ischemic as intermittent. Causes for ischemic priapism are many. Medications like antipsychotics are also responsible. α-adrenergic blockage is related to antipsychotics-associated priapism. The α-receptors mediate this that are located in the corpora cavernosa of the penis. A patient with risperidone-induced priapism is reported here. Switching to olanzapine resolved his problem. A drug which has α-1-blocking properties that are less marked is a preferred choice for switch. Unfortunately, we are yet to reach a consensus regarding what is the best choice of medication. It is pertinent to search for priapism risk factors. Thereafter, one should proceed to antipsychotic prescription. Not only the patient should know about this adverse effect but also one should know the need for urgent medical intervention.


HTML PDF Share
  1. Podolej GS, Babcock C, Kim J. Emergency department management of priapism [digest]. Emerg Med Pract 2017;19(1):S1–S2. PMID: 28027457.
  2. Kovac JR, Mak SK, Garcia MM, et al. A pathophysiology-based approach to the management of early priapism. Asian J Androl 2013;15:20–26. DOI: 10.1038/aja.2012.83
  3. Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin North Am 2007;34:631–642, viii. DOI: 10.1016/j.ucl.2007.08.006
  4. Andersohn F, Schmedt N, Weinmann S, et al. Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol 2010;30:68–71. DOI: 10.1097/JCP.0b013e3181c8273d
  5. Abd El, Salam MA, Foaad H. Chlorpromazine induced priapism from a single dose: an unusual complication of antipsychotic agent. Russ Open Med J 2017;6(3). DOI: 10.15275/rusomj.2017.0306
  6. Brichart N, Delavierre D, Peneau M, et al. Priapisme sous neuroleptiques. À propos de quatre patients. Prog Urol 2008;18:669–673. DOI: 10.1016/j.purol.2008.04.010
  7. Donizete da Costa F, Toledo da Silva Antonialli K, Dalgalarrondo P. Priapism and clozapine use in a patient with hypochondriacal delusional syndrome. Oxf Med Case Reports 2015;2015:229–231. DOI: 10.1093/omcr/omv020
  8. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
  9. Segraves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989;46:275–284. DOI: 10.1001/archpsyc.1989.01810030081011
  10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245. DOI: 10.1038/clpt.1981.154
  11. Burk BG, Nelson LA. Psychotropic-induced priapism in a treatment-refractory patient: a case report. J Pharm Pract 2021;34:309–313. DOI: 10.1177/0897190019885233
  12. Sood S, James W, Bailon M-J. Priapism associated with atypical antipsychotic medications: a review. Int Clin Psychopharmacol 2008;23:9–17. DOI: 10.1097/YIC.0b013e3282f1c1ef
  13. Doufik J, Otheman Y, Khalili L, et al. Antipsychotic-induced priapism and management challenges: a case report. Encephale 2014;40:518–521. DOI: 10.1016/j.encep.2013.11.004
  14. Saenz de Tejada I, Kim NN, Goldstein I, et al. Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum. Int J Impot Res 2000;12(Suppl 1):S20–S25. DOI: 10.1038/sj.ijir.3900500
  15. Bourgeois JA, Mundh H. Priapism associated with risperidone: a case report. J Clin Psychiatry 2003;64:15569. DOI: 10.4088/jcp.v64n0215d
  16. Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol 2003;170:1318–1324. DOI: 10.1097/01.ju.0000087608.07371.ca
  17. Paklet L, Abe AM, Olajide D. Priapism associated with risperidone: a case report, literature review and review of the South London and Maudsley hospital patients’ database. Ther Adv Psychopharmacol 2013;3:3–13. DOI: 10.1177/2045125312464104
  18. Muneer A, Alnajjar HM, Ralph D. Recent advances in the management of priapism. F1000Research 2018;7:37. DOI: 10.12688/f1000research.12828.1
  19. Scherzer ND, Reddy AG, Le TV, et al. Unintended consequences: a review of pharmacologically-induced priapism. Sexual Medicine Reviews, 2019;7(2):283–292. DOI: 10.1016/j.sxmr.2018.09.002
  20. Wang CS, Kao WT, Chen CD, et al. Priapism associated with typical and atypical antipsychotic medications. Int Clin Psychopharmacol 2006;21(4):245–248. DOI: 10.1097/00004850-200607000-00008
  21. Ridgley J, Raison N, Sheikh MI, et al. Ischaemic priapism: a clinical review. Turk J Urol 2017;43(1):1–8. DOI: 10.5152/tud.2017.59458
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.